CSIMarket
 


Catalyst Pharmaceuticals Inc   (CPRX)
Other Ticker:  
 
 

CPRX's Net Income Growth by Quarter and Year

Catalyst Pharmaceuticals Inc 's Net Income results by quarter and year




CPRX Net Income (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter December - 34.84 25.47 9.31
III Quarter September - -30.76 22.75 10.33
II Quarter June - 37.76 21.62 12.18
I Quarter March 23.28 29.57 13.24 7.66
FY   23.28 71.41 83.08 39.48



CPRX Net Income first quarter 2024 Y/Y Growth Comment
Catalyst Pharmaceuticals Inc reported decline in Net Income in the first quarter 2024 by -21.29% to $ 23.28 millions, from the same quarter in 2023.
The contraction in the first quarter 2024 Catalyst Pharmaceuticals Inc 's Net Income compares unfavorably to the Company's average Net Income jump of 54.16%.

Looking into first quarter 2024 results within Major Pharmaceutical Preparations industry 19 other companies have achieved higher Net Income growth. While Catalyst Pharmaceuticals Inc ' s Net Income fall of -21.29% ranks overall at the positon no. 1053 in the first quarter 2024.




CPRX Net Income ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter December - 36.79 % 173.58 % -18.62 %
III Quarter September - - 120.23 % -76.17 %
II Quarter June - 74.65 % 77.5 % 24.54 %
I Quarter March -21.29 % 123.34 % 72.85 % -26.56 %
FY   - -14.05 % 110.44 % -47.35 %

Financial Statements
Catalyst Pharmaceuticals Inc 's first quarter 2024 Net Income $ 23.28 millions CPRX's Income Statement
Catalyst Pharmaceuticals Inc 's first quarter 2023 Net Income $ 29.57 millions Quarterly CPRX's Income Statement
New: More CPRX's historic Net Income Growth >>


CPRX Net Income (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter December - - 11.96 % -9.87 %
III Quarter September - - 5.23 % -15.19 %
II Quarter June - 27.7 % 63.29 % 59.01 %
I Quarter March -33.19 % 16.1 % 42.21 % -33.04 %
FY (Year on Year)   - -14.05 % 110.44 % -47.35 %




Net Income first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #20
Healthcare Sector #82
Overall #1053

Net Income Y/Y Growth Statistics
High Average Low
217.97 % 54.16 % -76.17 %
(Sep 30 2020)   (Sep 30 2021)
Net Income first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #20
Healthcare Sector #82
Overall #1053
Net Income Y/Y Growth Statistics
High Average Low
217.97 % 54.16 % -76.17 %
(Sep 30 2020)   (Sep 30 2021)

Net Income by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Catalyst Pharmaceuticals Inc 's Q/Q Net Income Growth


Net Income Q/Q Growth Statistics
High Average Low
343.15 % 24.21 % -73.61 %
(Sep 30 2020)  


CPRX's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2024 Catalyst Pharmaceuticals Inc realized fall in Net Income from the fourth quarter by -33.19% to $ 23.28 millions, from $ 34.84 millions declared a quarter before.

Even cyclical factors which commonly energize I. Quarter 2024 performance, could not salvage the I. Quarter for the Catalyst Pharmaceuticals Inc , Robert Young, Healthcare sector veteran allocated in Dallas wrote and continued that average sequential Net Income growth is at 24.21% for the Major Pharmaceutical Preparations's company.

Within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Net Income quarter on quarter growth. While Catalyst Pharmaceuticals Inc 's Net Income growth quarter on quarter, overall rank is 1027.


Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #16
Healthcare Sector #66
Overall #1027
Net Income Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #16
Healthcare Sector #66
Overall #1027
Net Income Q/Q Growth Statistics
High Average Low
343.15 % 24.21 % -73.61 %
(Sep 30 2020)  


CPRX's I. Quarter Q/Q Net Income Comment
In the I. Quarter 2024 Catalyst Pharmaceuticals Inc reported fall in Net Income from the fourth quarter by -33.19% to $ 23.28 millions, from $ 34.84 millions released in the previous quarter.

Although seasonal influence usually energize I. Quarter 2024 Net Income, that clearly has not been substantial to salvage CPRX's I. Quarter outcome, Robert Young, Healthcare sector veteran allocated in Dallas said and mentioned that average quarter on quarter Net Income growth is at 24.21% for Catalyst Pharmaceuticals Inc .

Within Major Pharmaceutical Preparations industry 15 other companies have achieved higher Net Income quarter on quarter growth. While Catalyst Pharmaceuticals Inc 's Net Income growth quarter on quarter, overall rank is 1027.


Catalyst Pharmaceuticals Inc 's 12 Months Net Income Growth Year on Year


Net Income TTM Growth

12 Months Ending
(Mar 31 2024)
12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
Cumulative Net Income 12 Months Ending $ 65.12 $ 71.41 $ 62.04 $ 115.55 $ 99.41
Y / Y Net Income Growth (TTM) -34.49 % -14.05 % -7.29 % 112.02 % 120.61 %
Year on Year Net Income Growth Overall Ranking # 131 # 135 # 232 # 1567 # 1531
Seqeuential Net Income Change (TTM) -8.81 % 15.11 % -46.31 % 16.24 % 19.65 %
Seq. Net Income Growth (TTM) Overall Ranking # 483 # 390 # 613 # 714 # 769




Cumulative Net Income growth Comment
Catalyst Pharmaceuticals Inc 's cumulative 12 months Net Income continue to drop, but on the faster rate at -34.49% year on year, at Mar 31 2024 compare to the -14.05% decrease at Dec 31 2023. If the Catalyst Pharmaceuticals Inc 's fiscal year would end at Mar 31 2024, annual Net Income would be $65 millions.

Among companies within the Healthcare sector 12 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 131, from total ranking in previous quarter at 135.

Net Income TTM Q/Q Growth Statistics
High Average Low
656.67 %
75.54 %
-47.35 %
 

Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 13
Healthcare Sector # 13
Overall # 131

Net Income TTM Y/Y Growth Statistics
High Average Low
656.67 %
75.54 %
-47.35 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 50
S&P 500 # 483
Cumulative Net Income growth Comment
Catalyst Pharmaceuticals Inc 's cumulative 12 months Net Income continue to drop, but on the faster rate at -34.49% year on year, at Mar 31 2024 compare to the -14.05% decrease at Dec 31 2023. If the Catalyst Pharmaceuticals Inc 's fiscal year would end at Mar 31 2024, annual Net Income would be $65 millions.

Among companies within the Healthcare sector 12 other companies have achieved higher trailing twelve month Net Income growth. While Total ranking has impoved so far to 131, from total ranking in previous quarter at 135.

Net Income TTM Q/Q Growth Statistics
High Average Low
656.67 %
75.54 %
-47.35 %
 


Net Income TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 13
Healthcare Sector # 13
Overall # 131

Net Income TTM Y/Y Growth Statistics
High Average Low
656.67 %
75.54 %
-47.35 %
 


Net Income TTM Q/Q Growth Company Ranking
Within: No.
Industry # 13
Sector # 50
S&P 500 # 483




Other Net Income Growth
Major Pharmaceutical Preparations Industry Net Income Growth Trends and Statistics
Healthcare Sector Net Income Growth Statistics
Net Income Growth Trends for overall market
CPRX's Net Income Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Net Income Growth
Lowest Ranking Net Income Growth
Net Income Growth for CPRX's Competitors
Net Income Growth for Catalyst Pharmaceuticals Inc 's Suppliers
Net Income Growth for CPRX's Customers

You may also want to know
CPRX's Annual Growth Rates CPRX's Profitability Ratios CPRX's Asset Turnover Ratio CPRX's Dividend Growth
CPRX's Roe CPRX's Valuation Ratios CPRX's Financial Strength Ratios CPRX's Dividend Payout Ratio
CPRX's Roa CPRX's Inventory Turnover Ratio CPRX's Growth Rates CPRX's Dividend Comparisons



Companies with similar Net Income drop for the quarter ending Mar 31 2024 within Healthcare SectorY/Y Change %Net Income for the quarter ending Mar 31 2024
Iqvia Holdings Inc -0.35%$ -0.346 millions
Cadre Holdings inc -1.06%$ -1.057 millions
Exelixis Inc -1.95%$ -1.950 millions
Quest Diagnostics Inc-4.15%$ -4.147 millions
Progyny Inc -4.41%$ -4.412 millions
3m Company-4.89%$ -4.893 millions
Mettler Toledo International Inc-5.79%$ -5.794 millions
Utah Medical Products Inc-6.12%$ -6.122 millions
Abbott Laboratories-7.06%$ -7.056 millions
Entera Bio Ltd -7.90%$ -7.900 millions
National Research Corporation-8.69%$ -8.688 millions
Regeneron Pharmaceuticals Inc -11.71%$ -11.714 millions
Baxter International Inc -13.33%$ -13.333 millions
Phibro Animal Health Corporation-16.30%$ -16.302 millions
West Pharmaceutical Services Inc -17.64%$ -17.643 millions
Atrion Corporation-19.89%$ -19.885 millions
Tenx Keane Acquisition-19.93%$ -19.927 millions
Catalyst Pharmaceuticals Inc -21.28%$ -21.283 millions
American Shared Hospital Services-35.00%$ -35.000 millions
Amedisys Inc-41.41%$ -41.411 millions
Dariohealth Corp -44.05%$ -44.055 millions
Fonar Corporation-44.64%$ -44.638 millions
Envista Holdings Corporation-46.12%$ -46.119 millions
Viatris Inc -49.31%$ -49.310 millions
Pro dex Inc -50.11%$ -50.114 millions
Avantor Inc -50.29%$ -50.288 millions
Ir med Inc -51.33%$ -51.333 millions
Privia Health Group Inc -52.26%$ -52.265 millions
Orgenesis Inc -57.20%$ -57.202 millions
Oramed Pharmaceuticals Inc -57.52%$ -57.519 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com